“a favorable trend”

Local in-brain tumor recurrence showed a favorable trend for the 5-ALA group ( Figure 2 , p = 0.089).

Patients receiving the accommodative IOL referred more frequent visual disturbances with the exception of halos and vision difficulties at long distances, which occurred more in the FIL611PV group ( p < 0.001 in all cases). At 6-months after surgery all subjects referred a favorable trend towards glasses/contact lenses independence for far distances ( p = 0.09).

Although a favorable trend toward reduced distant recurrence in those patients treated with CC, the difference did not reach a statistical significance ( p = 0.094) (Figure 1 ).

In comparison to placebo, pioglitazone was linked with a favorable trend for macrovascular endpoints (19.7% vs. 21.7%; HR = 0.90, 95%CI 0.80-1.02, P = 0.095) [ 13 ].

However there was a favorable trend in grip strength in the RAPA (p=0.095) and MVC-RAPA (p=0.091) groups.

A favorable trend was observed in real-world PFS for patients treated with T-DXd as first- or second-line therapy compared with later lines (17 versus 15 months; p = 0.098).

A favorable trend in rwPFS was reported in patients receiving T-DXd as I/II line versus further lines (17 vs. 15 months; P = .098).

HSCT in CR1 was associated with significantly improved OS in intermediate-risk patients ( p = 0.003), showed a favorable trend in adverse-risk patients ( p = 0.098), and conferred no OS benefit in favorable-risk patients ( p = 0.351).

A favorable trend for increased transcription of Pax7 was also observed with matrix treatment (1.7×; P =0.1).

Among well-established predictors of ICI outcomes, 31 - 35 EBV status was not significantly associated with overall survival in patients treated with nivolumab plus chemotherapy although a favorable trend was observed (hazard ratio [HR], 3.86e-08 [95% CI, 0 to infinity]; log-rank test P = .10; Fig 3 A).

Although OS was not significantly different, there was a favorable trend in the HRR-altered group (median OS: 24.3 months [95% CI: 13.5–36.1 months] vs. 16.8 months [95% CI: 15.5–19.5 months], p = 0.100; Supplementary Figure 2B ).

Results demonstrated no significant associations between anthropometry characteristics (height or mass) and on-ice skating performance, except for a favorable trend between height and skating agility ( p < 0.10).

In this study, there was a favorable trend for median PFS for patients with CR who underwent ASCT within 9 months (median not reached vs. 89 months, P = 0.10) or 12 months (134 vs. 89 months, P = 0.18 of diagnosis (Table 3 ).

Additionally, we found a favorable trend (all p < 0.10) in vaccinated patients regarding myopericarditis (3 vs. 0 cases, p = 0.07), atrial fibrillation, and tinnitus/hearing loss.

Conversely, bisphosphonate therapy did not determine an improvement in terms of OS, even if a favorable trend was identified for treated patients (median, 7 versus 5 months, respectively; P = 0.105).

The UA showed better IPFS rates significantly related to male sex ( p = 0.049), a BED 12 of ≥42 Gy ( p = 0.006), and controlled extracranial disease ( p = 0.03); in the MA, a favorable trend towards LC ( p = 0.11) and higher BED ( p = 0.11) schedules maintained a correlation with improved IPFS rates, although statistical significance was not reached.

13 In contrast, another randomized phase II trial ( n = 101) comparing induction chemoradiotherapy (CRT) versus induction DCF highlighted the importance of radiotherapy (RT) for effective local control and survival improvement for unresectable LAESCC (cT4b); a favorable trend in 2-year OS for the CRT group (55.1% versus 34.7%, P = 0.11), although not statistically significant. 14 While R0 resection rates were similar (∼77%) and distant metastasis tended to be less frequent with DCF, induction CRT significantly reduced locoregional recurrence (local: 8% versus 30%, P = 0.03; regional: 8% versus 37%, P = 0.002).

2 d), and the MAP target achievement rate showed a favorable trend (51.16% vs. 27.27%, p = 0.111) ( Fig. 2 b).

While fmTLS + sarcomas showed a favorable trend towards prolonged time to distant progression (TTDP) at 5-years, this did not reach statistical significance ( p = 0.115) ( Figure 3 C).

Results indicated statistically significant benefit favoring CD-LD ER over CD-LD IR for PGI-C, CGI-C, percent of patients self-rated as much or very much improved and percent of patients clinician-rated as much or very much improved across all three dyskinesia groups except PGI-C for the TD group where a favorable trend ( p = 0.1174) was noted.

In a recent phase III trial in Korean patients with ED-SCLC, although OS and PFS were not significantly different between the EP and IP arms, there was a favorable trend toward the IP regimen (OS, 10.9 months vs. 10.3 months, P = 0.120; PFS, 6.5 months vs. 5.8 months, P = 0.115).

The analysis of secondary endpoints for MACEs also did not reach statistical significance, despite a favorable trend for the DK culotte (13% vs. 19%; p = 0.12).

A favorable trend was also observed for ORR (52.5% vs. 35.1%, p = 0.12) and OS (20.0 vs. 8.8 months; HR: 0.62; 95% CI: 0.35–1.10; p = 0.10) ( Figure 3 B).

Dyspnea showed a favorable trend that did not reach statistical significance (SMD = 0.33, 95%CI −0.11–0.77, p = 0.129), and no significant improvement was found in FEV1 (MD = 0.14 L, 95%CI −0.17–0.44, p = 0.190).

There were no associations of VF with any ADRB2 variant, whereas the ADRA2C 322–325 Ins/Del genotype had a favorable OR (0.39 [0.22, 0.72], P =0.002) and Del carriers exhibited a favorable trend (OR 0.69, P =0.13).